CG

CCME Global

514336 BSE
₹31.93 1.51 (4.96%)
Market Cap
₹144 Cr

CCME Global (CCME) share price was ₹31.93 at the 28 Oct 2026 close; market capitalisation ₹144 Cr; sector Healthcare. The share price fell 79.4% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue was under ₹1 Cr in both quarters and net profit was −₹0.26 Cr, against −₹0.12 Cr a year earlier (compared with Jun 2025). Promoters held 74.35% of CCME Global in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 33/100 (Poor) as of 28 Oct 2026.

Close 28 Oct 2026 ₹31.93 −122.91 −79.38% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹144 Cr
EBITDA
₹20.00 L
Return on Equity
-0.35%
Debt to Equity
0
Book Value
₹8.85
EPS (TTM)
−₹0.24
52W High
₹184.90
52W Low
₹26.41

Price-based figures as of 28 Oct 2026, 16:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Biotechnology

Anthem Biosciences
₹832.1581.1946,894 Cr15.410.24%19.45%26.78%2,161 Cr576 Cr
Advanced Enzyme Tech
₹259.7517.532,887 Cr1.782.05%10.31%13.58%800 Cr172 Cr
CCME Global (this company)
₹31.93—144 Cr3.610.00%-0.35%0.87%0 Cr-1 Cr
Shree Ganesh Biotech
₹0.44—18 Cr0.270.00%0.59%0.81%7 Cr-0 Cr
Genomic Valley Biotech
₹43.631,454.3313 Cr3.400.00%9.13%11.32%0 Cr0 Cr
Median 5 companies₹43.6381.19144 Cr3.400.00%9.13%11.32%7 Cr0 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
33 Poor
Overall score
Data confidence 86/100

Category scores

Quality Poor 13
Returns, margins, earnings quality 22%
Valuation Weak 42
Cheap vs sector & own history 24%
Growth Poor 1
Sales & profit trajectory 9%
Financial Health Strong 86
Solvency, leverage, coverage 9%
Momentum Poor 3
Trend strength, vol-adjusted 12%
Ownership Average 50
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

3
  • Stock is trading at 3.41 times its book value
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -2.66% over last 3 years.

Technical Indicators

Oscillators

BearishNeutralBullish

Bullish

Bearish
1
Neutral
6
Bullish
2

Overall

BearishNeutralBullish

Bearish

Bearish
11
Neutral
6
Bullish
2

Moving Averages

BearishNeutralBullish

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
-99%

change over 1 year

Net Income Growth
-124%

change over 1 year

Cash Flow Change
-99.27%

change over 1 year

EBITDA Margin Change
—

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0
0
0
0
0
3.67
0
0
0
0
0
0.04
0
Expenses
0.06
0.02
0.02
3.69
0.1
0.02
0.03
0.02
0.12
0.06
0.03
0.54
0.24
Operating Profit
-0.06
-0.02
-0.02
-3.69
-0.1
3.65
-0.03
-0.02
-0.12
-0.06
-0.03
-0.5
-0.24
OPM %
—
—
—
—
—
99.46%
—
—
—
—
—
-1250%
—
Other Income
0
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0.02
PBT
-0.06
-0.02
-0.02
-3.69
-0.1
3.65
-0.03
-0.02
-0.12
-0.06
-0.03
-0.5
-0.26
Tax %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Net Profit
-0.06
-0.02
-0.02
-3.69
-0.1
3.65
-0.03
-0.02
-0.12
-0.06
-0.03
-0.5
-0.26
EPS (₹)
-0.05
-0.02
-0.02
-2.84
-0.08
2.81
-0.02
-0.02
-0.09
-0.05
-0.02
-0.11
-0.06
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0.78
0
0
0.29
0.05
0
0
0
0
0
0
0
0.04
Expenses
0.93
0.07
0.07
0.49
0.1
0.1
0.12
0.12
0.14
3.8
0.17
0.75
0.87
Operating Profit
-0.15
-0.07
-0.07
-0.2
-0.05
-0.1
-0.12
-0.12
-0.14
-3.8
-0.17
-0.75
-0.83
OPM %
-19.23%
—
—
-68.97%
-100%
—
—
—
—
—
95.37%
-1775%
-2075%
Other Income
-0.09
0.42
0.07
0
0
0
0
0
0
0
3.67
0.04
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0.21
0
0
0
0
0
0
0
0
0
0
0
0.02
PBT
-0.45
0.35
0
-0.2
-0.05
-0.1
-0.12
-0.12
-0.14
-3.8
3.5
-0.71
-0.85
Tax %
0%
0%
—
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Net Profit
-0.44
0.35
0
-0.2
-0.05
-0.1
-0.12
-0.12
-0.14
-3.8
3.5
-0.71
-0.85
EPS (₹)
-0.62
0.36
0
-0.15
-0.04
-0.08
-0.09
-0.09
-0.11
-2.92
2.69
-0.16
-0.24
Div. Payout %
0%
0%
—
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
7.12
9.74
10
13
13
13
13
13
13
13
13
45.25
Reserves
-3.7
-3.35
-3.35
-3.55
-3.7
-3.8
-3.92
-4.04
-4.17
-7.97
-4.47
-5.18
Borrowings
0.17
0.2
0
0
0
0
0
0
0
0
0
0
Other Liabilities
0.93
0.51
0.03
0.07
0.08
0.12
0.12
0.13
0.14
0.18
0.3
5.24
Total Liabilities
4.52
7.1
6.68
9.52
9.38
9.32
9.2
9.09
8.97
5.21
8.83
45.31
Fixed Assets
0
0
0
0
0
0
0
0
0
0
0
0
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
4.66
0
0
0
0
0
0
0
0
Other Assets
4.52
7.1
6.68
4.86
9.38
9.32
9.2
9.09
8.97
5.21
8.83
45.31
Total Assets
4.52
7.1
6.68
9.52
9.38
9.32
9.2
9.09
8.97
5.21
8.83
45.31
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-4.86
-2.64
-0.25
1.68
-4.69
0.01
-0.12
-0.12
-0.09
0
0
5.1
Investing
0.77
0
0
-4.66
4.66
0
0
0
0
0
0
0
Financing
4.1
2.62
0.26
3
0
0
0.12
0.12
0.09
0
0
32.25
Net Cash Flow
0.01
-0.02
0.01
0.02
-0.03
0.01
0
0
-0.01
0
0
37.35
Free Cash Flow
-4.09
-2.64
-0.25
1.68
-4.69
0.01
-0.12
-0.12
-0.09
0
0
5.1
CFO/EBITDA
3,240
3,771
357
-840
9,380
-10
100
100
64
0
0
-680
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
229
—
—
62.93
292
—
—
—
—
—
—
—
Inventory Days
0
—
—
0
—
—
—
—
—
—
—
—
Cash Conversion Cycle
229
—
—
62.93
292
—
—
—
—
—
—
—
Working Capital Days
1,586
—
—
5,991
67,890
—
—
—
—
—
—
—
ROCE %
-16.62%
6.88%
0%
-2.48%
-0.53%
-1.08%
-1.31%
-1.33%
-1.57%
-54.83%
51.62%
-2.92%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view CCME Global insights

57 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

Promot.74.35%Public9.72%Others15.94%As ofSep 2026

Documents

Frequently Asked Questions about CCME Global

What does CCME Global Ltd do?
CCME Global Ltd, formerly Genesis IBRC India Ltd and SSK Lifestyles Ltd, is transitioning from a non-operational biotechnology business towards FMCG, commodities, and minerals trading, manufacturing, and import-export activities under new management.[1]
Where is CCME Global Ltd (CCME) listed?
CCME Global Ltd trades under code 514336 on the BSE.
Which sector does CCME Global Ltd belong to?
CCME Global Ltd is classified under the Healthcare sector, in the Biotechnology industry.
What is the market capitalisation of CCME Global Ltd?
CCME Global Ltd has a market capitalisation of ₹144.49 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of CCME Global Ltd?
Over the last 52 weeks CCME Global Ltd has traded between ₹26.41 and ₹184.9 as of 28 Oct 2026.
What is the Return on Equity (ROE) of CCME Global Ltd?
CCME Global Ltd reported a return on equity of -0.35%. Its debt-to-equity ratio is 0.00.

Company Information

CCME Global Ltd, formerly Genesis IBRC India Ltd and SSK Lifestyles Ltd, is transitioning from a non-operational biotechnology business towards FMCG, commodities, and minerals trading, manufacturing, and import-export activities under new management.[1]

Website genesisibrc.com
CEO Mr. Ravindranath Rajaram
Face Value ₹ 10
Shares Outstanding 4,52,50,896

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/514336.md for CCME Global Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month